OBJECTIVES: Amyloid-beta (Aβ) and tau pathologies are commonly observed among clinically normal older individuals at postmortem and can now be detected with in vivo neuroimaging. The association and interaction of these proteinopathies with prospective cognitive decline in normal aging and preclinical Alzheimer's disease (AD) remains to be fully elucidated. METHODS: One hundred thirty-seven older individuals (age = 76.3 ± 6.22 years) participating in the Harvard Aging Brain Study underwent Aβ (11 C-Pittsburgh compound B) and tau (18 F-flortaucipir) positron emission tomography (PET) with prospective neuropsychological assessments following PET imaging (mean number of cognitive visits = 2.8 ± 1.1). Tau and Aβ PET measures were assessed in regions of interest (ROIs) as well as vertex-wise map analyses. Cognitive change was evaluated with Memory and Executive Function composites. RESULTS: Higher levels of Aβ and tau were both associated with greater memory decline, but not with change in executive function. Higher cortical Aβ was associated with higher tau levels in all ROIs, independent of age, and very elevated levels of tau were observed primarily in clinically normal with elevated Aβ. A significant interaction between tau and Aβ was observed in both ROI and map-level analyses, such that rapid prospective memory decline was observed in participants who had high levels of both pathologies. INTERPRETATION: Our results are consistent with the supposition that both Aβ and tau are necessary for memory decline in the preclinical stages of AD. These findings may be relevant for disambiguating aging and early cognitive manifestations of AD, and to inform secondary prevention trials in preclinical AD. Ann Neurol 2019;00:1-3 ANN NEUROL 2019;85:181-193.
OBJECTIVES:Amyloid-beta (Aβ) and tau pathologies are commonly observed among clinically normal older individuals at postmortem and can now be detected with in vivo neuroimaging. The association and interaction of these proteinopathies with prospective cognitive decline in normal aging and preclinical Alzheimer's disease (AD) remains to be fully elucidated. METHODS: One hundred thirty-seven older individuals (age = 76.3 ± 6.22 years) participating in the Harvard Aging Brain Study underwent Aβ (11 C-Pittsburgh compound B) and tau (18 F-flortaucipir) positron emission tomography (PET) with prospective neuropsychological assessments following PET imaging (mean number of cognitive visits = 2.8 ± 1.1). Tau and Aβ PET measures were assessed in regions of interest (ROIs) as well as vertex-wise map analyses. Cognitive change was evaluated with Memory and Executive Function composites. RESULTS: Higher levels of Aβ and tau were both associated with greater memory decline, but not with change in executive function. Higher cortical Aβ was associated with higher tau levels in all ROIs, independent of age, and very elevated levels of tau were observed primarily in clinically normal with elevated Aβ. A significant interaction between tau and Aβ was observed in both ROI and map-level analyses, such that rapid prospective memory decline was observed in participants who had high levels of both pathologies. INTERPRETATION: Our results are consistent with the supposition that both Aβ and tau are necessary for memory decline in the preclinical stages of AD. These findings may be relevant for disambiguating aging and early cognitive manifestations of AD, and to inform secondary prevention trials in preclinical AD. Ann Neurol 2019;00:1-3 ANN NEUROL 2019;85:181-193.
Authors: Dorene M Rentz; Elizabeth C Mormino; Kathryn V Papp; Rebecca A Betensky; Reisa A Sperling; Keith A Johnson Journal: Brain Imaging Behav Date: 2017-04 Impact factor: 3.978
Authors: Michael C Donohue; Reisa A Sperling; Ronald Petersen; Chung-Kai Sun; Michael W Weiner; Paul S Aisen Journal: JAMA Date: 2017-06-13 Impact factor: 56.272
Authors: Mary M Machulda; Clint E Hagen; Heather J Wiste; Michelle M Mielke; David S Knopman; Rosebud O Roberts; Prashanthi Vemuri; Val J Lowe; Clifford R Jack; Ronald C Petersen Journal: Clin Neuropsychol Date: 2016-10-11 Impact factor: 3.535
Authors: Samuel N Lockhart; Michael Schöll; Suzanne L Baker; Nagehan Ayakta; Kaitlin N Swinnerton; Rachel K Bell; Taylor J Mellinger; Vyoma D Shah; James P O'Neil; Mustafa Janabi; William J Jagust Journal: Neuroimage Date: 2017-02-21 Impact factor: 6.556
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: Marta Marquié; Marc D Normandin; Charles R Vanderburg; Isabel M Costantino; Elizabeth A Bien; Lisa G Rycyna; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik L Debnath; Neil Vasdev; Bradford C Dickerson; Stephen N Gomperts; John H Growdon; Keith A Johnson; Matthew P Frosch; Bradley T Hyman; Teresa Gómez-Isla Journal: Ann Neurol Date: 2015-09-25 Impact factor: 10.422
Authors: Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling Journal: JAMA Neurol Date: 2014-11 Impact factor: 18.302
Authors: Reisa A Sperling; Dorene M Rentz; Keith A Johnson; Jason Karlawish; Michael Donohue; David P Salmon; Paul Aisen Journal: Sci Transl Med Date: 2014-03-19 Impact factor: 17.956
Authors: Prashanthi Vemuri; Val J Lowe; David S Knopman; Matthew L Senjem; Bradley J Kemp; Christopher G Schwarz; Scott A Przybelski; Mary M Machulda; Ronald C Petersen; Clifford R Jack Journal: Alzheimers Dement (Amst) Date: 2016-12-21
Authors: Saffire H Krance; Hugo Cogo-Moreira; Jennifer S Rabin; Sandra E Black; Walter Swardfager Journal: J Neurosci Date: 2019-07-26 Impact factor: 6.167
Authors: Kevin T Chen; Matti Schürer; Jiahong Ouyang; Mary Ellen I Koran; Guido Davidzon; Elizabeth Mormino; Solveig Tiepolt; Karl-Titus Hoffmann; Osama Sabri; Greg Zaharchuk; Henryk Barthel Journal: Eur J Nucl Med Mol Imaging Date: 2020-06-13 Impact factor: 9.236
Authors: Reisa A Sperling; Michael C Donohue; Rema Raman; Chung-Kai Sun; Roy Yaari; Karen Holdridge; Eric Siemers; Keith A Johnson; Paul S Aisen Journal: JAMA Neurol Date: 2020-06-01 Impact factor: 18.302
Authors: Xi Chen; Kaitlin E Cassady; Jenna N Adams; Theresa M Harrison; Suzanne L Baker; William J Jagust Journal: J Neurosci Date: 2020-11-20 Impact factor: 6.167
Authors: Anna Plachti; Shahrzad Kharabian; Simon B Eickhoff; Somayeh Maleki Balajoo; Felix Hoffstaedter; Deepthi P Varikuti; Christiane Jockwitz; Svenja Caspers; Katrin Amunts; Sarah Genon Journal: Brain Date: 2020-09-01 Impact factor: 13.501
Authors: Sandhitsu R Das; Long Xie; Laura E M Wisse; Nicolas Vergnet; Ranjit Ittyerah; Salena Cui; Paul A Yushkevich; David A Wolk Journal: Alzheimers Dement Date: 2019-09-06 Impact factor: 21.566